Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin

Journal of the American College of Cardiology

Volumn 68, Issue 21, 2016, Pages 2272-2283

  Chan, Yi Hsin ^a,b   Yeh, Yung Hsin ^a,b   See, Lai Chu ^a,b,c   Wang, Chun Li ^a,b   Chang, Shang Hung ^a,b   Lee, Hsin Fu ^a,b   Wu, Lung Sheng ^a,b   Tu, Hui Tzu ^b   Kuo, Chi Tai ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

acute kidney injury; atrial fibrillation; direct thrombin inhibitor; warfarin

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN;

ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; ASIAN; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG USE; FEMALE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; TAIWAN; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE; VERY ELDERLY; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; FOLLOW UP; INCIDENCE; PROCEDURES; RISK FACTOR; SURVIVAL RATE; TIME FACTOR; TRENDS;

ACUTE KIDNEY INJURY; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; DABIGATRAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TAIWAN; THROMBOEMBOLISM; TIME FACTORS; WARFARIN;

EID: 84997785122     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.08.063     Document Type: Article

References (29)

1. 1 Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
2. 2 Brodsky, S.V., Satoskar, A., Chen, J., et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis 54 (2009), 1121–1126.
3. 3 Brodsky, S.V., Nadasdy, T., Rovin, B.H., et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 80 (2011), 181–189.
4. 4 An, J.N., Ahn, S.Y., Yoon, C.H., et al. The occurrence of warfarin-related nephropathy and effects on renal and patient outcomes in Korean patients. PLoS One, 8, 2013, e57661.
5. 5 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. [published correction appears in N Engl J Med 2010;363:1877] N Engl J Med 361 (2009), 1139–1151.
6. 6 Ryan, M., Ware, K., Qamri, Z., et al. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. Nephrol Dial Transplant 29 (2014), 2228–2234.
7. 7 Shafi, S.T., Negrete, H., Roy, P., Julius, C.J., Sarac, E., A case of dabigatran-associated acute renal failure. WMJ 112 (2013), 173–175.
8. 8 Escoli, R., Santos, P., Andrade, S., Carvalho, F., Dabigatran-related nephropathy in a patient with undiagnosed IgA nephropathy. Case Rep Nephrol, 2015, 2015, 298261.
9. 9 Bohm, M., Ezekowitz, M.D., Connolly, S.J., et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol 65 (2015), 2481–2493.
10. 10 Wu, L.S., Chang, S.H., Chang, G.J., et al. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan. Cardiovasc Diabetol, 15, 2016, 56.
11. 11 Lin, H.Y., Chang, K.T., Chang, Y.H., et al. Nonapnea sleep disorders and the risk of acute kidney injury: a nationwide population-based study. Medicine (Baltimore), 95, 2016, e3067.
12. 12 Mehta, R.L., Kellum, J.A., Shah, S.V., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care, 11, 2007, R31.
13. 13 Wu, V.C., Wu, C.H., Huang, T.M., et al. Long-term risk of coronary events after AKI. J Am Soc Nephrol 25 (2014), 595–605.
14. 14 Cheng, C.L., Kao, Y.H., Lin, S.J., Lee, C.H., Lai, M.L., Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 20 (2011), 236–242.
15. 15 Chan, Y.H., Yen, K.C., See, L.C., et al. Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation. Stroke 47 (2016), 441–449.
16. 16 Austin, P.C., The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 33 (2014), 1242–1258.
17. 17 Ozcan, A., Ware, K., Calomeni, E., et al. 5/6 Nephrectomy as a validated rat model mimicking human warfarin-related nephropathy. Am J Nephrol 35 (2012), 356–364.
18. 18 Yanagita, M., Gas6, warfarin, and kidney diseases. Clin Exp Nephrol 8 (2004), 304–309.
19. 19 Ware, K., Brodsky, P., Satoskar, A.A., et al. Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation. J Am Soc Nephrol 22 (2011), 1856–1862.
20. 20 Chang, C.C., Liou, H.H., Wu, C.L., et al. Warfarin slows deterioration of renal function in elderly patients with chronic kidney disease and atrial fibrillation. Clin Interv Aging 8 (2013), 523–529.
21. 21 Narasimha Krishna, V., Warnock, D.G., Saxena, N., Rizk, D.V., Oral anticoagulants and risk of nephropathy. Drug Saf 38 (2015), 527–533.
22. 22 Wheeler, D.S., Giugliano, R.P., Rangaswami, J., Anticoagulation-related nephropathy. J Thromb Haemost 14 (2016), 461–467.
23. 23 Ware, K.M., Vance, J.C., Muni, N., et al. Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?. Am J Hypertens 28 (2015), 182–189.
24. 24 Caldeira, D., Goncalves, N., Pinto, F.J., Costa, J., Ferreira, J.J., Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 24 (2015), 757–764.
25. 25 Hori, M., Matsumoto, M., Tanahashi, N., et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: the J-ROCKET AF study. Circ J 76 (2012), 2104–2111.
26. 26 Eriksson, B.I., Borris, L.C., Friedman, R.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358 (2008), 2765–2775.
27. 27 Kakkar, A.K., Brenner, B., Dahl, O.E., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372 (2008), 31–39.
28. 28 Hori, M., Connolly, S.J., Zhu, J., et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 44 (2013), 1891–1896.
29. 29 Cameron, C., Coyle, D., Richter, T., et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open, 4, 2014, e004301.